Sign In
Buy EARS
$0.750
-0.0010 (-0.133%)
At Close: May 27, 2022
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
01:00pm, Friday, 13'th Sep 2019
Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today a
Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
01:00pm, Wednesday, 11'th Sep 2019
Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today a
Auris Medical Announces Appointment of New Chief Financial Officer
11:00am, Wednesday, 04'th Sep 2019
Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today a
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
01:00pm, Monday, 26'th Aug 2019
Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today a
New Strong Sell Stocks for August 23rd
02:21pm, Friday, 23'rd Aug 2019
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
New Strong Sell Stocks for August 22nd
02:06pm, Thursday, 22'nd Aug 2019
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Auris Medical Provides Business Update and Reports First Half 2019 Financial Results
11:00am, Thursday, 15'th Aug 2019
Hamilton, Bermuda, Aug. 15, 2019 -- Enrollment of first patient in TRAVERS Phase 2 trial with AM-125 in acute vertigoEnrollment completed in Phase 1b trial with AM-201 in.
Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
12:30pm, Tuesday, 30'th Jul 2019
The TRAVERS trial will enroll a total of 138 patients who suffer from acute vertigo following surgical removal of a vestibular schwannoma, a tumor growing behind the inner ear. In addition, oral beta
Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain
01:00pm, Wednesday, 03'rd Jul 2019
The trial enrolled in total 50 healthy volunteers who received either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks. “Completing enrollment for this proof-o
